Home
VERV
VERV News

Latest Verve Therapeutics Inc. (VERV) News on July 26, 2024

MT Newswires

17 days ago

RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk

Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?

Insider Monkey

18 days ago

Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

25 days ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

GlobeNewswire

a month ago

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

One Verve Therapeutics Insider Raised Stake By 29% In Previous Year

Simply Wall St.

a month ago

One Verve Therapeutics Insider Raised Stake By 29% In Previous Year

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

2 months ago

Verve Therapeutics Names Troy Lister Chief Scientific Officer

Verve Therapeutics Announces Leadership Update

GlobeNewswire

2 months ago

Verve Therapeutics Announces Leadership Update

Verve Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

2 months ago

Verve Therapeutics to Participate in Upcoming Investor Conferences

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 05/16/2024

Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

3 months ago

Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week

Simply Wall St.

3 months ago

Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week

Verve Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Verve Therapeutics First Quarter 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Zacks

3 months ago

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

3 months ago

Verve Therapeutics: Q1 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

Verve moves forward with backup base editing therapy

BioPharma Dive

3 months ago

Verve moves forward with backup base editing therapy

Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

GlobeNewswire

3 months ago

Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

3 months ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

After a Serious Setback, Is Verve Therapeutics a Buy?

Motley Fool

4 months ago

After a Serious Setback, Is Verve Therapeutics a Buy?

Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More

Zacks

4 months ago

Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

Zacks

4 months ago

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects

Investor's Business Daily

4 months ago

Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects

Verve Falls as Gene-Editing Trial Paused on Safety Issues

Bloomberg

4 months ago

Verve Falls as Gene-Editing Trial Paused on Safety Issues

Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects

Investor's Business Daily

4 months ago

Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects

Reuters

4 months ago

UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

Reuters

4 months ago

Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

Verve Therapeutics Announces Updates on its PCSK9 Program

GlobeNewswire

4 months ago

Verve Therapeutics Announces Updates on its PCSK9 Program

Verve pauses base editing trial, shifts strategy after treatment side effect

BioPharma Dive

4 months ago

Verve pauses base editing trial, shifts strategy after treatment side effect

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)

Simply Wall St.

5 months ago

New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)

Verve Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Verve Therapeutics Full Year 2023 Earnings: Beats Expectations

GuruFocus.com

5 months ago

Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023

Associated Press Finance

5 months ago

Verve Therapeutics: Q4 Earnings Snapshot

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

5 months ago

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

InvestorPlace

5 months ago

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

Zacks

5 months ago

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

3 Gene Editing Stocks With Unprecedented Surge Potential

InvestorPlace

5 months ago

3 Gene Editing Stocks With Unprecedented Surge Potential

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare

Motley Fool

5 months ago

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

6 months ago

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

InvestorPlace

6 months ago

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Associated Press Finance

6 months ago

Merchants Bancorp: Q4 Earnings Snapshot

Coeur Reports Record 2023 Fourth Quarter Production at its Newly Expanded Rochester Operation and Provides Update on First Half 2024 Crusher Commissioning and Ramp-Up Progress

Business Wire

6 months ago

Coeur Reports Record 2023 Fourth Quarter Production at its Newly Expanded Rochester Operation and Provides Update on First Half 2024 Crusher Commissioning and Ramp-Up Progress

Merchants Bancorp Reports Fourth Quarter 2023 Results

PR Newswire

6 months ago

Merchants Bancorp Reports Fourth Quarter 2023 Results

New Strong Buy Stocks for January 29th

Zacks

6 months ago

New Strong Buy Stocks for January 29th

Verve Therapeutics, Inc. (NASDAQ:VERV) is a favorite amongst institutional investors who own 64%

Simply Wall St.

6 months ago

Verve Therapeutics, Inc. (NASDAQ:VERV) is a favorite amongst institutional investors who own 64%

The S&P 500 Just Hit an All-Time High. Here's 1 Artificial Intelligence (AI) Stock to Buy and Hold Hand Over Fist.

Motley Fool

6 months ago

The S&P 500 Just Hit an All-Time High. Here's 1 Artificial Intelligence (AI) Stock to Buy and Hold Hand Over Fist.

ZipRecruiter to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

Business Wire

6 months ago

ZipRecruiter to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

Sallie Mae (SLM) Lags Q4 Earnings Estimates

Zacks

6 months ago

Sallie Mae (SLM) Lags Q4 Earnings Estimates

Strength Seen in Zuora (ZUO): Can Its 6.1% Jump Turn into More Strength?

Zacks

6 months ago

Strength Seen in Zuora (ZUO): Can Its 6.1% Jump Turn into More Strength?

Factors Setting the Tone for Malibu Boats' (MBUU) Q2 Earnings

Zacks

6 months ago

Factors Setting the Tone for Malibu Boats' (MBUU) Q2 Earnings

11 Stocks That Will Make You Rich in 5-10 Years

Insider Monkey

6 months ago

11 Stocks That Will Make You Rich in 5-10 Years

Reuters

6 months ago

UPDATE 1-Kaman to be taken private by Arcline Investment Management in $1.8 bln deal

Reuters

6 months ago

Kaman to be bought by Arcline Investment Management in $1.8 billion deal

Business Wire

6 months ago

Kaman to be Acquired by Arcline for $1.8 Billion

Sonic Automotive Schedules Release of 2023 Fourth Quarter and Full Year Financial Results

Business Wire

6 months ago

Sonic Automotive Schedules Release of 2023 Fourth Quarter and Full Year Financial Results

7 Mighty Healthcare Stocks Changing the Game of Medicine

InvestorPlace

6 months ago

7 Mighty Healthcare Stocks Changing the Game of Medicine

First Majestic Produces 6.6 Million AgEq Oz in Q4 2023 and 26.9 Million AgEq Oz in 2023; Announces 2024 Production and Cost Guidance and Conference Call Details

Newsfile

6 months ago

First Majestic Produces 6.6 Million AgEq Oz in Q4 2023 and 26.9 Million AgEq Oz in 2023; Announces 2024 Production and Cost Guidance and Conference Call Details

RLJ Lodging Trust Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates

Business Wire

6 months ago

RLJ Lodging Trust Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates

NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, February 23

Business Wire

6 months ago

NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, February 23

3 Stocks to Buy in the Booming Field of Gene Editing

InvestorPlace

6 months ago

3 Stocks to Buy in the Booming Field of Gene Editing

Monro, Inc. to Report Third Quarter Fiscal 2024 Earnings on January 24, 2024

Business Wire

7 months ago

Monro, Inc. to Report Third Quarter Fiscal 2024 Earnings on January 24, 2024

Why Fisker Stock Continued to Plunge Today

Motley Fool

7 months ago

Why Fisker Stock Continued to Plunge Today

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

Investor's Business Daily

7 months ago

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

Is Kaman Corporation (NYSE:KAMN) Trading At A 20% Discount?

Simply Wall St.

7 months ago

Is Kaman Corporation (NYSE:KAMN) Trading At A 20% Discount?

Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

7 months ago

Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade

Zacks

7 months ago

Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade

Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet

Zacks

7 months ago

Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet

Business Wire

7 months ago

Douglas Emmett Announces Dates for Its 2023 Fourth Quarter Earnings Results and Live Conference Call

MAG Announces the Appointment of Tom Peregoodoff to the Board of Directors as Part of Planned Board Succession

GlobeNewswire

7 months ago

MAG Announces the Appointment of Tom Peregoodoff to the Board of Directors as Part of Planned Board Succession

Dentsply Sirona Declares Quarterly Cash Dividend

GlobeNewswire

7 months ago

Dentsply Sirona Declares Quarterly Cash Dividend

Is MiMedx Group, Inc. (NASDAQ:MDXG) Trading At A 50% Discount?

Simply Wall St.

7 months ago

Is MiMedx Group, Inc. (NASDAQ:MDXG) Trading At A 50% Discount?

Business Wire

7 months ago

Douglas Emmett Declares Quarterly Cash Dividend

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

8 months ago

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

Insider Sell Alert: Director SIMON WILLIAM E JR Sells 91,000 Shares of Douglas Emmett Inc (DEI)

GuruFocus.com

8 months ago

Insider Sell Alert: Director SIMON WILLIAM E JR Sells 91,000 Shares of Douglas Emmett Inc (DEI)

We Wouldn't Be Too Quick To Buy U.S. Physical Therapy, Inc. (NYSE:USPH) Before It Goes Ex-Dividend

Simply Wall St.

8 months ago

We Wouldn't Be Too Quick To Buy U.S. Physical Therapy, Inc. (NYSE:USPH) Before It Goes Ex-Dividend

Polly and MeridianLink Partner to Help Mortgage Lenders Improve Scale and Profitability in Today’s Market

Business Wire

9 months ago

Polly and MeridianLink Partner to Help Mortgage Lenders Improve Scale and Profitability in Today’s Market

Earnings Preview: SeaWorld (SEAS) Q3 Earnings Expected to Decline

Zacks

9 months ago

Earnings Preview: SeaWorld (SEAS) Q3 Earnings Expected to Decline

Share on Social Networks: